Stocktoria
AtaiBeckley Inc. ATAI
AtaiBeckley Inc. (ATAI) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $4.1M at a -16142.0% net margin.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ATAI | AtaiBeckley Inc. | 4/9 | — | — | — |
| CPHI | CHINA PHARMA HOLDINGS, INC. | 4/9 | -3.85 | — | — |
| CRVO | CervoMed Inc. | 1/9 | -12.9 | — | — |
| MRKR | Marker Therapeutics, Inc. | 2/9 | — | — | — |
| CAMP | Camp4 Therapeutics Corp | 3/9 | -4.88 | — | — |
| PCYN | PROCYON CORP | 3/9 | 3.03 | — | — |
| ENSC | Ensysce Biosciences, Inc. | — | — | — | — |
About AtaiBeckley Inc.
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.
FAQ
Is ATAI financially healthy?
AtaiBeckley Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does ATAI pay a dividend?
No, AtaiBeckley Inc. does not currently pay a dividend.
How profitable is ATAI?
In FY2025, AtaiBeckley Inc. had a net margin of -16142.0% and a return on equity of -297.3%.
What is the analyst price target for ATAI?
The average Wall-Street price target for AtaiBeckley Inc. is $14.00, about 93.6% above the recent price, from 12 analysts.
Is ATAI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on AtaiBeckley Inc.: a Piotroski F-score of 4/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.